Form 8-K January 05, 2015			
UNITED STATES			
SECURITIES AND EXCHANGE COMMISSION			
Washington, D.C. 20549			
FORM 8-K			
CURRENT REPORT			
Pursuant to Section 13 or 15(d) of			
the Securities Exchange Act of 1934			
Date of Report (Date of Earliest Event Reported): January 5, 2015			
Protalix BioTherapeutics, Inc.			
(Exact name of registrant as specified in its charter)			

Florida (State or other jurisdiction of incorporation)	001-33357 (Commission File Number)	65-0643773 (IRS Employer Identification No.)	
2 Snunit Street Science Park, POB 455 Carmiel, Israel (Address of principal execu	20100 tive offices) (Zip Code)		
Registrant's telephone number, including area code +972-4-988-9488			
(Former name or former address, if changed since last report.)			
* * *	clow if the Form 8-K filing is in e following provisions (see Ge	ntended to simultaneously satisfy the filing obligation of neral Instruction A.2. below):	
" Soliciting m	naterial pursuant to Rule 14a-12	425 under the Securities Act (17 CFR 230.425) 2 under the Exchange Act (17 CFR 240.14a-12) d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	

" Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

On January 5, 2015, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing the Company's newly implemented strategy for accelerated growth. The release includes an estimate of the Company's current cash position. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 8.01. Other Events

As set forth in Item 2.02, on January 5, 2015, the Company issued a press release announcing its newly implemented strategy for accelerated growth.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

Press release dated January 5, 2015 (disclosure referenced in Item. 2.02 is furnished with this report, not filed).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

Date: January 5, 2015 By: /s/ Moshe Manor

Name: Moshe Manor Title: President and

Chief Executive Officer

3